Abstract
Background
To study the incidence of vancomycin-associated acute kidney injury (VA-AKI) in Hong Kong and identify risk factors for VA-AKI.
Method
Patients with vancomycin prescription and blood level measurement in 2012–2016 were identified using the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System. Acute kidney injury was defined using KDIGO criteria. Patients without creatinine measurements, steady-state trough vancomycin level or who had vancomycin treatment < 3 days were excluded. Results were analyzed using SPSS version 22.0. Logistic regression was used to identify the predictors for VA-AKI. Odds ratio and 95% confidence interval were estimated.
Results
One thousand four hundred fifty patients were identified as VA-AKI from 12,758 records in Hong Kong in 2012–2016. The incidence was respectively 10.6, 10.9, 11.3, 12.2, 11.2% from 2012 to 2016. The incidence of VA-AKI was 16.3, 12.2, 11.3 and 6.2% in patients aged 1–12, 12–60, elderly aged > 60 and newborn and infants, respectively. Baseline creatinine, serum trough vancomycin level, systematic disease history including respiratory failure, hypertension, congestive heart failure, chronic renal failure, anemia and type II diabetes, and concomitant diuretics, piperacillin-tazobactam (PTZ) and meropenem prescription were significantly higher in VA-AKI patients older than 12 years. Logistic regression showed that older age group, higher baseline creatinine, serum trough vancomycin level, respiratory failure, chronic renal failure and congestive heart failure, concomitant diuretics, PTZ and meropenem prescription, and longer hospital stay were all associated with increased risk of VA-AKI.
Conclusion
The incidence of VA-AKI in Hong Kong is low but shows no decline. Patients with higher baseline creatinine, multi-organ diseases and multiple drugs administration should have their vancomycin level monitored to decrease the risk of VA-AKI.
Keywords: Vancomycin, Acute kidney injury
Background
Methicillin-resistant Staphylococcus aureus (MRSA) has gained considerable attention due to its high morbidity, limited effective treatments available and increased incidence [1]. Vancomycin has been recommended as the first line treatment for MRSA infections by American, European, and Chinese guidelines for infectious diseases control and management control for antibiotics [2–5]. However, the significant nephrotoxicity limits the use of vancomycin in daily clinical practice. It has been reported the incidence of VA-AKI ranges from 0% to over 40% [6].
AKI is one of the examples of nephrotoxicity that accounts for about 1.7 million deaths every year worldwide. The consequences of AKI can be severe, ranging from hospitalization to life-long dialysis and transplantation. From a recent meta-analysis, the pooled incidence of AKI was 19.4% in eastern Asia [7]. Drugs are the third main cause of AKI [8]. The prognosis in drug-associated AKI is poor, especially in critically ill patients.
In Hong Kong, there is limited published literature on the incidence of drug-induced nephrotoxicity. A previous study reported an incidence of 23.1% for VA-AKI in a hospital [9]. A systematic population-wide study is clearly needed, in view of the serious implications of this potentially preventable and reversible condition. Therefore, we investigated the incidence of VA-AKI in Hong Kong from 2012 to 2016, characterized patients with VA-AKI as well as identified predictors for the development of VA-AKI.
Methods
Study design and data sources
A retrospective study was conducted using Clinical Data Analysis and Report System (CDARS), a database managed by the Hong Kong Hospital Authority (HA). HA is the sole public hospital service provider in Hong Kong. More than 90% of Hong Kong residents use the public hospital services [10]. CDARS captures patient records in Hong Kong in all public hospitals and outpatient clinics since 1993. This database provides a convenient platform for pharmaco-epidemiological studies [11].
All patients’ records with vancomycin prescription and measurement of serum drug level from January 2012 to December 2016 in Hong Kong were retrieved from CDARS. Demographics, laboratory parameters, concomitant medications and co-morbidities were collected as the covariates. Patients with vancomycin prescription and steady-state serum trough vancomycin level were included as the exposure status. Patients who had no baseline and follow-up concentration of creatinine within 48 h, vancomycin treatment < 3 days or steady state serum trough vancomycin level were excluded. Trough concentrations were defined as the results from the samples taken within 1 h of the next due dose. The first trough concentration was measured after 3 days of vancomycin administration.
Definition of AKI
With the use of Kidney Disease Improving Global Outcomes (KDIGO) criteria [12], patients with AKI were identified as increase in serum creatinine (SCr) by 0.3 mg/dL or more within 48 h, or as a 1.5~1.9 times increase in SCr from baseline. These patients were at least of stage I in severity. Stage II was defined as 2~2.9 times increase in SCr from baseline. Stage III was defined as 3 times increase in SCr from baseline or increase in SCr to ≥4 mg/dL. Vancomycin-associated AKI was the main outcome for the study. Patients without VA-AKI were classified as non-VA-AKI group.
Statistical analysis
IBM SPSS statistics version 22.0 (IBM SPSS Statistics, Armonk, NY, USA) was used for data analysis. Descriptive statistics were expressed as frequency for categorical data or median (interquartile range) for continuous variables. With reference to a vancomycin therapeutic guideline [5], vancomycin concentration was categorized into 4 groups: < 10.0 mg/L, 10.0~15.0 mg/L, 15.0~20.0 mg/L, > 20.0 mg/L. Continuous variables were compared among groups using one-way ANOVA and Kruskal-Wallis tests as appropriate. Categorical variables were compared among groups using Pearson Chi-square test. Logistic regression was used to estimate odd ratios (ORs) and 95% confidence interval (CI). Firstly, univariate logistic models were used to explore the relationship between VA-AKI and risk factors, including gender, age, route of administration, baseline creatinine, tough vancomycin level, concomitant drugs, length of stay and death in hospital. Secondly, to determine whether there was significant collinearity between continuous variables, collinearity diagnostics were performed using variance inflation factor (VIF) and tolerance values. If tolerance value is close to zero or VIF is greater than 10, there may be multi-collinearity. Thirdly, four models adjusted by different confounders were applied to analyse the possible predicators. Model 1: adjusted for demographics (age, sex); Model 2: additionally adjusted for comorbidities; Model 3: additionally adjusted for medications; Model 4: additionally adjusted for baseline creatinine and length of stay. Predictor variables were entered if P < 0.05 and removed if P > 0.10 in the stepwise model. A two-tailed P < 0·05 was considered statistically significant. A two-tailed P < 0.05 will be considered statistically significant.
Results
A total of 12,758 patients were included in this study from 2012 to 2016 in Hong Kong (Fig. 1). The median age of patients with VA-AKI was 72 years old, and 64.2% of cases were male. The prescription of vancomycin increased gradually and doubled in 2016 compared with 2012. The incidence of VA-AKI remained at approximately 11.4% (Table 1).
Fig. 1.
A flow diagram for inclusion of study samples
Table 1.
Incidence and demographic characters of patients with VA-AKI in Hong Kong from 2012 to 2016
| 2012 | 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|---|
| Annual admissions | 1,466,788 | 1,508,489 | 1,532,926 | 1,592,148 | 1,629,346 |
| Vancomycin prescription | 3310 | 3510 | 4132 | 5597 | 6694 |
| Enrolled patients | 1542 | 1709 | 2446 | 3374 | 3687 |
| Male | 63.1% | 62.5% | 62.9% | 63.7% | 64.0% |
| Female | 36.9% | 37.5% | 37.1% | 36.3% | 36.0% |
| Age | 71.7 (52.8, 83.0) | 71.6 (55.8, 81.9) | 73.8 (58.5, 83.4) | 71.8 (58.1, 83.5) | 76.5 (62.1, 85.7) |
| VA-AKI cases | 164 | 186 | 276 | 410 | 414 |
| Incidence of VA-AKI | 10.6% | 10.9% | 11.3% | 12.2% | 11.2% |
Table 2 shows the characteristics of patients with VA-AKI stratified by age group. The incidence of VA-AKI in patients aged 1 to 12 was the highest (16.3%), following patients aged 12 to 60 (12.2%), elderly aged over 60 (11.3%) and newborn and infants (6.2%). The median age of VA-AKI patients was slightly younger than patients without VA-AKI in elderly group, yet older than patients without VA-AKI in patients less than 60 years old. There was no significant gender difference between VA-AKI and non-VA-AKI groups in all age groups. The main route of administration was injection and parenteral, with several cases of oral, eye drop and intraperitoneal route. The incidence of VA-AKI was distinctively higher in newborn and infants receiving parenteral administration (P < 0.001). The baseline creatinine and trough vancomycin concentration in the VA-AKI group were significantly higher than non-VA-AKI group in patients older than 12 years old (P < 0.001). However, there were no significant difference in patients aged under 12. Along with the increase of trough vancomycin level, the incidence of VA-AKI either in cumulative incidence or in each AKI stage showed a significantly upward trend (P < 0.001) (Fig. 2). Compared to non-VA-AKI group, more patients with VA-AKI aged over 12 had comorbidities including respiratory failure, essential hypertension, congestive heart failure, chronic renal failure, anaemia and type II DM. There were more comorbidities in VA-AKI patients between 12 to 60 years old compared with non-VA-AKI group in the same age group. Patients with VA-AKI aged over 12 were more likely to receive diuretics, piperacillin-tazobactam (PTZ) and meropenem, while more angiotensin converting enzyme inhibitors (ACEI) prescripts were found in patients with VA-AKI from 1 to 12 years old, more ACEI, angiotensin II receptor blocker (ARB), non-steroidal anti-inflammatory drugs (NSAID) prescripts in VA-AKI group from 12 to 60 years old, and more aminoglycoside and amphotericin B prescripts in VA-AKI patients over 60 years old. Patients over 60 years old with VA-AKI were hospitalized for longer duration. VA-AKI group had a significantly higher mortality in hospital compared with non-VA-AKI group.
Table 2.
Comparison of clinical characteristics in VA-AKI and non-VA-AKI patients stratified by age groups
| New-borns and infants | Children 1 to 12 years of age | Adolescents above 12 years of age and adults | Elderly patients aged over 60 years | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-VA-AKI | VA-AKI | P value | Non-VA-AKI | VA-AKI | P value | Non-VA-AKI | VA-AKI | P value | Non-VA-AKI | VA-AKI | P value | |
| N | 406 (93.8%) | 27 (6.2%) | – | 123 (83.7%) | 24 (16.3%) | – | 2523 (87.8%) | 350 (12.2%) | – | 8256 (88.7%) | 1049 (11.3%) | – |
| Age | 0.0 (0.0, 0.1) | 0.0 (0.0, 0.2) | 0.034 | 4.5 (2.7, 7.7) | 4.8 (1.4, 6.3) | 0.277 | 50.6 (41.1, 56.0) | 52.2 (43.8, 56.6) | 0.037 | 79.9 (71.1, 86.4) | 78.1 (69.0, 84.6) | < 0.001 |
| Male | 59.1% | 55.6% | 0.840 | 52.8% | 70.8% | 0.120 | 65.0% | 66.6% | 0.590 | 63.1% | 63.4% | 0.865 |
| Strains of bacteria | ||||||||||||
| Streptococcus | 1 | 0 | 0.594 | 5 | 0 | 0.231 | 51 | 3 | 0.039 | 82 | 14 | 0.104 |
| Enterococcus | 11 | 1 | 1 | 0 | 10 | 1 | 106 | 20 | ||||
| Staphylococcus | 55 | 2 | 9 | 2 | 158 | 27 | 1061 | 145 | ||||
| Route of Administration | ||||||||||||
| injection | 98.0% | 85.2% | < 0.001 | 94.3% | 95.8% | 0.763 | 82.1% | 85.7% | 0.049 | 76.2% | 78.6% | 0.279 |
| parenteral | 2.0% | 14.8% | 5.7% | 4.2% | 17.6% | 13.7% | 23.5% | 21.1% | ||||
| oral | – | – | – | – | 0.2% | 0.3% | 0.2% | 0.2% | ||||
| Eye drop | – | – | – | – | 0.0% | 0.3% | 0.0% | 0.1% | ||||
| Intraperitoneal | – | – | – | – | 0.1% | 0.0% | 0.0% | 0.2% | ||||
| Chemistry Profile | ||||||||||||
| Baseline Creatinine (μmol/L) | 58.2 (41.0, 74.0) | 44.0 (20.0, 69.0) | 0.060 | 36.0 (28.4, 46.0) | 31.5 (23.8, 46.3) | 0.256 | 66.0 (51.0, 94.0) | 112.2 (68.0, 269.0) | < 0.001 | 79.0 (58.3, 122.0) | 111.0 (72.7, 196.5) | < 0.001 |
| Tough Vancomycin (mg/L) | 7.2 (5.0, 10.8) | 9.7 (5.8, 14.7) | 0.075 | 5.2 (3.3, 9.2) | 11.7 (5.7, 19.7) | < 0.001 | 7.8 (5.1, 12.5) | 13.8 (8.6, 20.5) | < 0.001 | 11.3 (7.8, 16.2) | 15.0 (9.9, 21.1) | < 0.001 |
| Comorbidities | ||||||||||||
| Pneumonia | 7.1% | 11.1% | 0.439 | 41.5% | 25.0% | 0.171 | 21.6% | 28.0% | 0.009 | 38.5% | 37.9% | 0.723 |
| Respiratory failure | 9.4% | 11.1% | 0.733 | 12.2% | 25.0% | 0.115 | 20.4% | 26.6% | 0.010 | 19.4% | 24.1% | < 0.001 |
| Essential hypertension | 0.2% | 0.0% | 1.000 | 0.8% | 0.0% | 1.000 | 17.1% | 28.0% | < 0.001 | 50.3% | 53.6% | 0.048 |
| Congestive heart failure | 2.0% | 0.0% | 1.000 | 1.6% | 4.2% | 0.417 | 7.3% | 18.0% | < 0.001 | 19.3% | 24.9% | < 0.001 |
| Urinary tract infection | 4.9% | 3.7% | 1.000 | 5.7% | 8.3% | 0.641 | 15.4% | 15.4% | 1.000 | 38.4% | 34.5% | 0.015 |
| Chronic renal failure | 0.2% | 0.0% | 1.000 | 0.8% | 8.3% | 0.069 | 7.3% | 24.0% | < 0.001 | 6.5% | 16.0% | < 0.001 |
| Fever | 3.9% | 7.4% | 0.311 | 34.1% | 29.2% | 0.814 | 25.3% | 24.9% | 0.896 | 36.1% | 34.9% | 0.429 |
| Sepsis | 7.1% | 3.7% | 1.000 | 14.6% | 12.5% | 1.000 | 13.4% | 15.4% | 0.318 | 21.3% | 21.4% | 0.938 |
| Anaemia | 12.3% | 11.1% | 1.000 | 18.7% | 20.8% | 0.781 | 21.4% | 27.7% | 0.009 | 25.8% | 29.9% | 0.004 |
| Type II DM | – | – | – | – | – | – | 12.1% | 18.9% | 0.001 | 27.0% | 30.3% | 0.024 |
| Number of comorbidities | ||||||||||||
| 0 | 66.0% | 55.6% | 0.379 | 30.1% | 37.5% | 0.732 | 29.9% | 19.4% | < 0.001 | 10.2% | 9.6% | 0.114 |
| 1 | 23.2% | 37.0% | 31.7% | 20.8% | 24.9% | 18.9% | 15.0% | 12.4% | ||||
| 2 | 7.9% | 3.7% | 21.1% | 25.0% | 19.3% | 20.3% | 18.2% | 18.9% | ||||
| > 3 | 3.0% | 3.7% | 17.1% | 16.7% | 25.8% | 41.4% | 56.5% | 59.1% | ||||
| Concomitant drugs | ||||||||||||
| Inotropic agents | 2.5% | 0.0% | 1.000 | 4.1% | 4.2% | 1.000 | 4.5% | 8.8% | 0.002 | 11.4% | 12.8% | 0.184 |
| Diuretics | 71.2% | 74.1% | 0.829 | 48.0% | 62.5% | 0.265 | 54.2% | 72.7% | < 0.001 | 64.2% | 73.5% | < 0.001 |
| ACEI | 2.7% | 7.4% | 0.191 | 6.5% | 33.3% | 0.001 | 19.4% | 30.6% | < 0.001 | 32.5% | 34.2% | 0.285 |
| ARB | – | – | – | 0.8% | 0.0% | 1.000 | 5.2% | 11.5% | < 0.001 | 7.5% | 9.0% | 0.079 |
| PTZ | 12.3% | 7.4% | 0.758 | 26.8% | 29.2% | 0.806 | 62.0% | 73.3% | < 0.001 | 62.0% | 67.9% | < 0.001 |
| Meropenem | 53.0% | 44.4% | 0.430 | 41.5% | 66.7% | 0.027 | 51.2% | 59.4% | 0.006 | 42.5% | 47.6% | 0.002 |
| Aminoglycoside | 54.4% | 33.3% | 0.045 | 59.3% | 45.8% | 0.262 | 52.7% | 50.9% | 0.557 | 45.6% | 49.4% | 0.024 |
| Cefepime | 89.4% | 100.0% | 0.094 | 84.6% | 70.8% | 0.141 | 69.3% | 72.7% | 0.225 | 64.6% | 66.2% | 0.317 |
| Amphotericin B | 6.9% | 11.1% | 0.429 | 8.1% | 20.8% | 0.072 | 8.6% | 8.5% | 1.000 | 2.1% | 3.2% | 0.019 |
| NSAIDs | 1.2% | 0.0% | 1.000 | 31.7% | 29.2% | 1.000 | 30.1% | 21.8% | 0.002 | 15.7% | 14.7% | 0.367 |
| Number of concomitant drugs | ||||||||||||
| 0 | 2.0% | 0.0% | 0.685 | 0.8% | 0.0% | 0.738 | 2.7% | 1.8% | < 0.001 | 2.9% | 2.0% | < 0.001 |
| 1 | 10.1% | 7.4% | 15.4% | 12.5% | 8.0% | 3.0% | 8.2% | 4.9% | ||||
| 2 | 24.9% | 33.3% | 24.4% | 16.7% | 16.9% | 7.6% | 16.4% | 13.1% | ||||
| > 3 | 63.1% | 59.3% | 59.3% | 70.8% | 72.4% | 87.6% | 72.5% | 80.0% | ||||
| Length of Stay | 85.0 (47.8, 122.0) | 107.0 (31.0, 155.0) | 0.608 | 36.5 (21.0, 61.0) | 39.5 (12.3, 87.5) | 0.778 | 50.0 (27.0, 87.0) | 44.0 (25.0, 85.0) | 0.249 | 40.0 (23.0, 67.0) | 33.0 (20.0, 58.0) | < 0.001 |
| Death in hospital | 8.4% | 18.5% | 0.075 | 9.8% | 25.0% | 0.037 | 16.8% | 31.4% | < 0.001 | 28.4% | 51.5% | < 0.001 |
Abbreviations: Type II DM Type II diabetes metillus, ACEI angiotension converting enzyme inhibitors, ARB angiotensin II receptor blocker, PTZ piperacillin-tazobactam, NSAIDs non-steroidal antiinflammatory drugs
Fig. 2.
The incidence of vancomycin associated AKI stratified by vancomycin level (mg/L) and AKI stage
Logistic analysis shows the possible risk factors associated with VA-AKI (Table 3). Using both univariate logistic model and adjusted logistic models showed that older age, baseline creatinine, trough vancomycin level, the comorbidities including essential hypertension, anaemia, respiratory failure, type II DM, chronic renal failure and congestive heart failure, concomitant drugs including diuretics, ACEI, ARB, PTZ, and meropenem were all associated with higher risk for the development of VA-AKI. Regarding collinearity, the highest VIF and the lowest tolerance values were 1.016 and 0.87, respectively, which suggests the absence of significant collinearity. Compared with newborns and infants, older age groups had lower ORs for development of VA-AKI (OR of children 1 to 12 years of age: 2.93 (95%CI [1.63, 5.27], OR of adults and adolescents above 12 years of age: 2.09 (95%CI [1.39, 3.13], OR of elderly patients: 1.91 (95%CI [1.29, 2.84], respectively). Most of these predicators had positive relationships with VA-AKI, yet, urinary tract infection had a negative relationship with VA-AKI (OR: 0.75 (95%CI [0.66, 0.86]). After adjusted for gender, age, comorbidities, concomitant drugs, baseline creatinine and length of stay in various models with increasing confounders, vancomycin, especially vancomycin concentration over 10 were still significant predicators for VA-AKI. Compared to the vancomycin level less than 10.0 mg/L group, higher vancomycin level had higher OR for VA-AKI onset in univariate logistic model (OR of 10.0~15.0 level: 1.55 (95%CI [1.34, 1.81], OR of 15.1~20.0 level: 2.50 (95%CI [2.13, 2.93], OR of > 20.0 level: 3.89 (95%CI [3.34, 4.53], respectively).
Table 3.
Predicators for VA-AKI in Hong Kong
| OR | Model 1 | Model 2 | Model 3 | Model 4 | |
|---|---|---|---|---|---|
| Male | 0.96 (0.86, 1.08) | – | – | – | – |
| Age | |||||
| Newborn and infants | Reference | – | – | – | – |
| Children 1 to 12 years of age | 2.93 (1.63, 5.27)* | – | – | – | – |
| Adults and adolescents above 12 years of age | 2.09 (1.39, 3.13)* | – | – | – | – |
| Elderly patients | 1.91 (1.29, 2.84) | – | – | – | – |
| Chemistry profile | |||||
| Baseline creatinine | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | – |
| Trough vancomycin level | 1.04 (1.04, 1.05)* | 1.05 (1.04, 1.05)* | 1.04(1.04, 1.05)* | 1.04 (1.04,1.05)* | 1.04 (1.04,1.05)* |
| Classification of vancomycin level (mg/L) | |||||
| < 10.0 | Reference | Reference | Reference | Reference | Reference |
| 10.0~15.0 | 1.55 (1.34, 1.81)* | 1.68 (1.44, 1.96)* | 1.63 (1.39, 1.92)* | 1.62 (1.38,1.89)* | 1.64 (1.40,1.93)* |
| 15.1~20.0 | 2.50 (2.13, 2.93)* | 2.75 (2.33, 3.24)* | 2.62 (2.21, 3.11)* | 2.61 (2.20,3.08)* | 2.62 (2.21,3.11)* |
| > 20.0 | 3.89 (3.34, 4.53)* | 4.29 (3.67, 5.02)* | 3.93 (3.34, 4.63)* | 4.05 (3.45,4.77)* | 4.07 (3.46,4.79)* |
| Comorbidities | |||||
| Pneumonia | 1.06 (0.94, 1.19) | 1.07 (0.96, 1.21) | – | – | – |
| Essential hypertension | 1.23 (1.10, 1.38)* | 1.33 (1.18, 1.50)* | – | – | |
| Urinary tract infection | 0.87 (0.77, 0.98)# | 0.88 (0.77, 1.00) | – | – | – |
| Fever | 0.97 (0.86, 1.09) | 0.98 (0.87, 1.11) | – | – | – |
| Anemia | 1.29 (1.14, 1.45)* | 1.30 (1.15, 1.48)* | – | – | – |
| Respiratory failure | 1.39 (1.22, 1.58)* | 1.39 (1.22, 1.58)* | – | – | – |
| Type II DM | 1.25 (1.10, 1.41)* | 1.28 (1.13, 1.46)* | – | – | – |
| Sepsis | 1.03 (0.90, 1.19) | 1.05 (0.91, 1.20) | – | – | |
| Chronic renal failure | 3.17 (2.72, 3.70)* | 3.18 (2.72, 3.71)* | – | – | – |
| Congestive heart failure | 1.56 (1.37, 1.79)* | 1.63 (1.42, 1.87)* | – | – | – |
| Concomitant drugs | |||||
| Inotropic agents | 1.26 (1.05, 1.50)# | 1.28 (1.07, 1.53)# | 1.19 (0.99,1.43) | – | – |
| Diuretics | 1.71 (1.51, 1.94)* | 1.72 (1.51, 1.95)* | 1.49 (1.31,1.70)* | – | |
| ACEI | 1.25 (1.11, 1.41)* | 1.27 (1.12, 1.43)* | 1.11 (0.98,1.27) | – | – |
| ARB | 1.46 (1.20, 1.77)* | 1.47 (1.21, 1.79)* | 1.15 (0.94,1.42) | – | – |
| PTZ | 1.39 (1.24, 1.57)* | 1.41 (1.25, 1.59)* | 1.39 (1.23,1.57)* | – | – |
| Meropenem | 1.29 (1.16, 1.45)* | 1.29 (1.15, 1.44)* | 1.23 (1.10,1.39)* | – | – |
| Aminoglycoside | 1.71 (0.96, 1.22) | 1.07 (0.95, 1.21)# | 1.05 (0.94,1.18) | – | – |
| Cefepime | 1.31 (1.01, 1.71) | 1.29 (0.99, 1.69) | 1.04 (0.92,1.18) | – | |
| Amphotericin B | 0.84 (0.73, 0.98)# | 0.84 (0.72, 0.97) | 1.24 (0.95,1.63) | – | – |
| NSAIDs | 1.00 (1.00, 1.00)# | 1.00 (1.00, 1.00) | 0.93 (0.80,1.09) | – | – |
| Length of Stay | 0.97 (0.86, 1.09) | 0.98 (0.87, 1.11) | 1.00 (1.00,1.00) | 1.00 (1.00,1.00)# | – |
Data is expressed as odds ratio (95% confidence interval)
-Not available or not in the equation
Model 1: adjusted for age and gender
Model 2: additionally, adjusted for comorbidities;
Model 3: additionally, adjusted for medications;
Model 4: additionally, adjusted for baseline creatinine and length of stay
*p < 0.001 #p < 0.05
Discussion
In this study involving 12,578 patients on vancomycin, the incidence of VA-AKI was 11.4% in Hong Kong in 2012–2016. Compared with non-VA-AKI group, VA-AKI patients older than 12 years had significant higher level or frequency in the baseline creatinine, trough vancomycin level, systematic disease history including respiratory failure, essential hypertension, congestive heart failure, chronic renal failure, anaemia and type II DM, and concomitant drugs usage including diuretics, PTZ and meropenem. VA-AKI group had a significantly higher mortality in hospital compared with non-VA-AKI group. The incidence of VA-AKI increased with increased vancomycin level. Stepwise logistic regression showed that older age group, higher vancomycin level, comorbidities including respiratory failure, chronic renal failure and congestive heart failure, concomitant drugs including diuretics, PTZ and meropenem and length of stay were all independent risk factors for the development of VA-AKI.
This study is the first large scale investigation of VA-AKI in Hong Kong. In previous studies, the incidence of VA-AKI in Chinese varied from 2.4 to 45% [9, 13–16] (Additional file 1: Table S1). The difference of estimated incidence is due to different populations, sample sizes, inclusion criteria and AKI definition. In USA, the incidence of VA-AKI declined from 42.6% in 2007 to 14.1% in 2017 [17, 18]. This might be due to doctors’ awareness of the toxicity of vancomycin and improvements in vancomycin purity. Our study reports a lower incidence of VA-AKI than the previous study [9], since the large database is less prone to publication and other biases.
In the literature, nephrotoxicity occurs in 1–9% of neonates receiving currently recommended doses, and 6–14% of paediatric patients [19–21]. Since these studies were all based on different population, the incidence of VA-AKI cannot be compared. Our study compared the incidence of VA-AKI in different age group based on the same population. By age group, the order of incidence from high to low was children from 1 to 12 years old (16.3%), adolescents above 12 years of age and adults (12.2%), elderly patients aged over 60 years (11.3%), new-borns and infants (6.2%). The characters of young patients with VA-AKI were different from elderly patients. The median of trough vancomycin in patients under 60 years old were all lower than 10 mg/L, yet the incidence of VA-AKI still accounted for a sizeable proportion. In new-borns and infants receiving parenteral administration the incidence of VA-AKI was distinctively higher.
There have been studies on the risk factors for VA-AKI in the past [22–24]. Like previous studies, a positive correlation between VA-AKI and increasing vancomycin trough concentrations and baseline serum creatinine was found in this study. The association between age and VA-AKI was controversial, mostly with a positive correlation [24]. While some studies explored after controlling for comorbid condition, medications and renal function, age is not associated with AKI [25]. In this study, we found age was correlated with VA-AKI, yet compared with new-borns and infants age group, older age group had less OR for development of VA-AKI. Concomitant administration of diuretics, PTZ and meropenem could increase the incidence of nephrotoxicity [22, 26, 27], except concomitant NSAIDs seems to have a protective role for VA-AKI. In each age group, VA-AKI incidence was lower in patients with concomitant NSAIDs. We confirmed that concomitant chronic renal failure, congestive heart failure and respiratory failure increased the risk for VA-AKI, as in a previous study in China [15]. Although vancomycin administrated by eye-drops, oral and intraperitoneal has low bioavailability, a previous study reported AKI development was related with the usage of topical fortified gentamicin and vancomycin eyedrops [28]. Similarly, serum concentration of vancomycin could also be observed in VA-AKI group in different routes of administration in this study. The incidence and mechanism of VA-AKI in uncommon routes of administration remains uncertain, yet the possible risk for AKI development should be noticed.
Several explanations have been put forth on the cause of VA-AKI, including impurities in vancomycin [29], critically-ill patients with complications and on multiple drugs, and lack of suitable control patients. A randomized controlled trial was conducted to identify the relationship between vancomycin and the development of AKI. Patients were randomized to continuation of dose-optimized vancomycin or early switch to an alternative antimicrobial agent. The incidence of AKI in both groups was similar (32.7 to 31.4% [P = 0.89]) [30], but this was a small study of 103 patients in a single center.
The strength of this study was that it was population-based and territory-wide, and used a very large database. In the limited literature, the incidence of AKI in Hong Kong was reported as 11.7% [31], similar to the incidence of VA-AKI in our study. It provides good evidence that dosing and monitoring practices of vancomycin in Hong Kong are sound. However, there were limitations. Since it was an observational study, causation cannot be proven. Patients with VA-AKI could have other reasons for AKI, such as comorbidities, hypotension, sepsis and concomitant drugs. It is distinctly difficult to determine the actual risk factors of VA-AKI.
Conclusion
In summary, the incidence of VA-AKI in Hong Kong is low but shows no decline. As there is increased usage of vancomycin to combat MRSA, there should be increased awareness of VA-AKI. Patients with higher baseline creatinine, chronic diseases and multiple drugs are at risk of VA-AKI and should have their vancomycin level monitored. Our findings facilitate the development of strategies and guidelines to prevent vancomycin-associated AKI.
Supplementary information
Additional file 1: Table S1. Literature review of incidence of VA-AKI in Chinese. The key points of previous publications regarding to VA-AKI in Chinese were summarized including the region, patients, definition of AKI, incidence of VA-AKI and references.
Acknowledgements
QX was a recipient of a Dr. Cheng Yu Tung Fellowship.
Abbreviations
- ACEI
Angiotension converting enzyme inhibitors
- ARB
Angiotensin II receptor blocker
- CDARS
Clinical Data Analysis and Report System
- CI
Confidence interval
- HA
Hong Kong Hospital Authority
- KDIGO
Kidney Disease Improving Global Outcomes
- MRSA
Methicillin-resistant Staphylococcus aureus
- NSAID
Non-steroidal anti-inflammatory drugs
- ORs
Odd ratios
- PTZ
Qpiperacillin-tazobactam
- SCr
Serum creatinine
- VA-AKI
Vancomycin-associated acute kidney injury
Authors’ contributions
QX made substantial contributions to conception, design and drafting the manuscript. XYZ, LZ and ZHQ were involved in revising and drafting the manuscript for important intellectual content. MFT and BMYC made substantial contributions to conception and design, acquisition of data and revising of the final version of the manuscript. All authors have approved the final version of the manuscript and its conclusions, and take public responsibility for the accuracy and integrity.
Funding
No available funding.
Availability of data and materials
The datasets used and/or analysed during the current study available from CDARS on reasonable request.
Ethics approval and consent to participate
This project has been approved by Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKW IRB Reference Number: UW 19–378). This is a retrospective study and all patients included were identified anonymously.
Consent for publication
The authors all consent for publication.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information accompanies this paper at 10.1186/s12882-020-1704-4.
References
- 1.Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–292. doi: 10.1093/cid/cir034. [DOI] [PubMed] [Google Scholar]
- 2.Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020–3025. doi: 10.1093/jac/dkw254. [DOI] [PubMed] [Google Scholar]
- 3.Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20(Suppl 4):19–36. doi: 10.1111/1469-0691.12450. [DOI] [PubMed] [Google Scholar]
- 4.Mensa J, Soriano A, Llinares P, et al. Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus. Rev Esp Quimioter. 2013;26(Suppl 1):1–84. [PubMed] [Google Scholar]
- 5.Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325–327. doi: 10.1086/600877. [DOI] [PubMed] [Google Scholar]
- 6.Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017;102(3):459–469. doi: 10.1002/cpt.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Mehta RL, Cerdá J, Burdmann EA, et al. International society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616–2643. doi: 10.1016/S0140-6736(15)60126-X. [DOI] [PubMed] [Google Scholar]
- 8.Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006;12(6):538–543. doi: 10.1097/01.ccx.0000247448.94252.5a. [DOI] [PubMed] [Google Scholar]
- 9.You JH, Chow SS, Lui JW, Ip M. New target concentrations for vancomycin in Hong Kong. Int J Antimicrob Agents. 2011;37(1):83–84. doi: 10.1016/j.ijantimicag.2010.09.003. [DOI] [PubMed] [Google Scholar]
- 10.Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63(5):1182–1189. doi: 10.1002/art.30277. [DOI] [PubMed] [Google Scholar]
- 11.Sing CW, Wong IC, Cheung BM, Chan JC, Chu JK, Cheung CL. Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study. Pharmacoepidemiol Drug Saf. 2017;26(3):248–255. doi: 10.1002/pds.4156. [DOI] [PubMed] [Google Scholar]
- 12.Ad-hoc working group of E. Fliser D, Laville M, et al. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263–4272. doi: 10.1093/ndt/gfs375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Dong MH, Wang JW, Wu Y, Chen BY, Yu M, Wen AD. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China. Int J Infect Dis. 2015;37:125–128. doi: 10.1016/j.ijid.2015.06.025. [DOI] [PubMed] [Google Scholar]
- 14.Wei WX, Qin XL, Cheng DH, Lu H, Liu TT. Retrospective analysis of vancomycin treatment outcomes in Chinese paediatric patients with suspected gram-positive infection. J Clin Pharm Ther. 2016;41(6):650–656. doi: 10.1111/jcpt.12437. [DOI] [PubMed] [Google Scholar]
- 15.Liu Y, Yin Y, Liu XZ, et al. Retrospective analysis of Vancomycin nephrotoxicity in elderly Chinese patients. Pharmacology. 2015;95(5–6):279–284. doi: 10.1159/000381783. [DOI] [PubMed] [Google Scholar]
- 16.Shen WC, Chiang YC, Chen HY, et al. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton) 2011;16(8):697–703. doi: 10.1111/j.1440-1797.2011.01488.x. [DOI] [PubMed] [Google Scholar]
- 17.Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107–1115. doi: 10.1016/j.clinthera.2007.06.014. [DOI] [PubMed] [Google Scholar]
- 18.Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis. J Hosp Med. 2017;12(2):77–82. doi: 10.12788/jhm.2684. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lestner JM, Hill LF, Heath PT, Sharland M. Vancomycin toxicity in neonates: a review of the evidence. Curr Opin Infect Dis. 2016;29(3):237–247. doi: 10.1097/QCO.0000000000000263. [DOI] [PubMed] [Google Scholar]
- 20.McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158(3):422–426. doi: 10.1016/j.jpeds.2010.08.019. [DOI] [PubMed] [Google Scholar]
- 21.Abouelkheir M, Alsubaie S. Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam. Pediatr Int. 2018;60(2):136–141. doi: 10.1111/ped.13463. [DOI] [PubMed] [Google Scholar]
- 22.Choi YC, Saw S, Soliman D, et al. Intravenous Vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017;51(11):937–944. doi: 10.1177/1060028017720946. [DOI] [PubMed] [Google Scholar]
- 23.Bhargava V, Malloy M, Fonseca R. The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit. BMC Pediatr. 2017;17(1):50. doi: 10.1186/s12887-017-0777-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Conway EL, Sellick JA, Horey A, et al. Decreased mortality in patients prescribed vancomycin after implementation of antimicrobial stewardship program. Am J Infect Control. 2017;45(11):1194–7. [DOI] [PubMed]
- 25.Carreno JJ, Jaworski A, Kenney RM, Davis SL. Comparative incidence of nephrotoxicity by age group among adult patients receiving Vancomycin. Infect Dis Ther. 2013;2(2):201–208. doi: 10.1007/s40121-013-0022-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Mellen CK, Ryba JE, Rindone JP. Does Piperacillin-Tazobactam increase the risk of nephrotoxicity when used with Vancomycin: a meta-analysis of observational trials. Curr Drug Saf. 2017;12(1):62–66. doi: 10.2174/1574886311666161024164859. [DOI] [PubMed] [Google Scholar]
- 27.Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.Pharmacotherapy. 2014;34(7):662–9. [DOI] [PubMed]
- 28.Tang RK, Tse RK. Acute renal failure after topical fortified gentamicin and vancomycin eyedrops. J Ocul Pharmacol Ther. 2011;27(4):411–413. doi: 10.1089/jop.2010.0163. [DOI] [PubMed] [Google Scholar]
- 29.Nambiar S, Madurawe RD, Zuk SM, et al. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother. 2012;56(6):2819–2823. doi: 10.1128/AAC.05344-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Carreno JJ, Kenney RM, Divine G, Vazquez JA, Davis SL. Randomized controlled trial to determine the efficacy of early switch from Vancomycin to Vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT) Ann Pharmacother. 2017;51(3):185–193. doi: 10.1177/1060028016673858. [DOI] [PubMed] [Google Scholar]
- 31.Szeto CC. Perspectives on acute kidney injury strategy: Hong Kong. Nephrology (Carlton) 2018;23(Suppl 4):104–106. doi: 10.1111/nep.13450. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 1: Table S1. Literature review of incidence of VA-AKI in Chinese. The key points of previous publications regarding to VA-AKI in Chinese were summarized including the region, patients, definition of AKI, incidence of VA-AKI and references.
Data Availability Statement
The datasets used and/or analysed during the current study available from CDARS on reasonable request.